Eczematous eruption during anti-interleukin 17 treatment of psoriasis: an emerging condition

Major advances in psoriasis pathogenesis have resulted in the development of effective new drugs for its treatment. In particular, biologics have revolutionized disease management.1 Tumour necrosis factor (TNF)‐α inhibitors were the first in 2000.1 Thus, adverse cutaneous reactions to their use have been extensively investigated.2 However, the anti‐interleukin (IL)‐17 agents secukinumab, ixekizumab and brodalumab have been introduced more recently for moderate‐to‐severe psoriasis.1 As a consequence, possible skin adverse events as a result of their use are not so fully elucidated. Eczematous eruption (EE) has been previously reported in 5–20% of patients with various inflammatory diseases treated with anti‐TNF‐α.3 Conversely, only anecdotal cases of EE induced by anti‐IL‐12/23 or anti‐IL‐17 in patients with psoriasis have been described.